Satralizumab added to immunosuppressant treatment may reduce relapse in some cases of neuromyelitis optica spectrum disorder.
The phase 3, randomized, double-masked, placebo-controlled SAkuraSky trial included 83 patients randomly assigned 1:1 to receive satralizumab (Genentech) or placebo in addition to baseline immunotherapy treatment. Eight of 41 patients (20%) who received satralizumab relapsed compared with 18 of 42 patients (43%) who received placebo.
Satralizumab is a monoclonal antibody that targets the interleukin-6 receptor, which is thought to be a key driver of the inflammation that
Uncategorized